# LAG-3 Pioneer Immutep Fails Phase 3 Lung Cancer Study, Stock Crashes 88%

- slug: lag-3-pioneer-immutep-fails-phase-3-lung-cancer-study-stock-crashes-88
- date: 2026-03-14
- category: Biotech & Life Sciences

Australian biotech's lead drug eftilagimod alfa falls short in pivotal NSCLC trial, dealing another blow to the once-promising LAG-3 checkpoint target

---